Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer.
Tamiya A, Osuga M, Harada D, Isa SI, Taniguchi Y, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, Koh Y. Tamiya A, et al. Among authors: nakamura k. Lung Cancer. 2024 Sep;195:107917. doi: 10.1016/j.lungcan.2024.107917. Epub 2024 Aug 3. Lung Cancer. 2024. PMID: 39116552 Free article.
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Ito S, Asahina H, Honjo O, Tanaka H, Honda R, Oizumi S, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. Ito S, et al. Among authors: nakamura k. Lung Cancer. 2021 Jun;156:12-19. doi: 10.1016/j.lungcan.2021.04.011. Epub 2021 Apr 15. Lung Cancer. 2021. PMID: 33872943 Free article.
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, Koh Y. Taniguchi Y, et al. Among authors: nakamura k. BMC Pulm Med. 2024 Aug 24;24(1):407. doi: 10.1186/s12890-024-03212-5. BMC Pulm Med. 2024. PMID: 39182046 Free PMC article.
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
Mizugaki H, Oizumi S, Fujita Y, Harada T, Nakahara Y, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Asahina H, Nakamura K, Nakamura H, Hosoda F, Yagishita S, Hamada A. Mizugaki H, et al. Among authors: nakamura h, nakamura k. Eur J Cancer. 2022 Jan;160:227-234. doi: 10.1016/j.ejca.2021.10.024. Epub 2021 Nov 30. Eur J Cancer. 2022. PMID: 34862083
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S. Ikezawa Y, et al. Among authors: nakamura k, nakamura a. Cancer Sci. 2022 Jun;113(6):2109-2117. doi: 10.1111/cas.15361. Epub 2022 Apr 15. Cancer Sci. 2022. PMID: 35377496 Free PMC article.
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. Morinaga D, et al. Among authors: nakamura k. Cancer Med. 2023 May;12(10):11525-11541. doi: 10.1002/cam4.5889. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999734 Free PMC article.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Tsuji K, et al. Among authors: nakamura k. Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287788 Free PMC article.
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Ikezawa Y, et al. Among authors: nakamura k, nakamura a. Cancer Med. 2024 Jul;13(14):e70036. doi: 10.1002/cam4.70036. Cancer Med. 2024. PMID: 39030894 Free PMC article.
Initial adjustments in the dosage and rest period of gemcitabine plus cisplatin therapy for patients with incurable biliary tract cancer based on baseline estimated glomerular filtration rate (eGFR) values may be crucial for treatment outcomes and the preservation of renal function.
Masumoto T, Yamai T, Nakamura K, Kamizono K, Sugioka H, Miyazaki T, Kiyota R, Maegawa Y, Shimizu T, Kawai S, Tawara S, Inoue T, Yakushijin T. Masumoto T, et al. Among authors: nakamura k. J Gastrointest Oncol. 2024 Oct 31;15(5):2277-2285. doi: 10.21037/jgo-24-330. Epub 2024 Oct 24. J Gastrointest Oncol. 2024. PMID: 39554560 Free PMC article.
14,813 results
You have reached the last available page of results. Please see the User Guide for more information.